6-day antibiotic cellulitis therapy results in faster, greater relapse than 12-day course

April 21, 2018

Madrid, Spain: Cellulitis treated with a six-day course of intravenous antibiotic flucloxacillin resulted in greater rates of relapse at 90 days post treatment despite having similar short-term results to that of the 12-day course, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) [1].

Cellulitis, a skin infection that can become life threatening, usually takes hold through a cut in the skin and is often caused by Staphylococcus or Streptococcus. The recommended antibiotic treatment duration is 10 to 14 days. As many infections have seen their antibiotic therapy duration shortened in recent years presenting author, Dr Duncan Rowan Cranendonk and his team expected to be able to shorten cellulitis treatment in a similar way. They investigated how six days of treatment compared to a 12-day course of antibiotics in patients hospitalised with cellulitis.

The primary outcome for patients participating in this study was for a cure by day 14 without a relapse by day 28. In the 12-day group, 35 patients, or 49.3%, were cured without relapse by day 28. In the six-day group, 35 patients, or 50.7%, reached the primary outcome. The study showed that the secondary patient outcome with the modified cure assessment was also similar, with 53 patients, or 74.6%, in the longer-term treatment group cured without relapse after 28 days compared with 49 patients, or 71%, in the shorter-term group. However, the secondary outcome of relapse rate by day 90, showed differences in effectiveness of the treatment duration.

"After initial cure without relapse, relapse rates at day 90 were higher in the six-day group than in the 12-day group," Cranendonk said. "Patients with a shorter course of therapy showed significantly faster and more frequent relapses by day 90."

Cranendonk said the results showed that "short-term outcomes are not everything." He also said physicians should consider developing a better measure for what it means to be "cured". Cellulitis for example lacks solid outcomes like a microbiological cure, and the "cured" verdict is still one made by clinicians, which makes it subject to interpersonal variation, he explained. An earlier small trial found no differences in outcome between short and standard therapy duration when looking at young healthy outpatients.

"Our trial is the exact opposite; we had elderly hospitalized patients with a lot of comorbidity. This is the population clinicians are likely to see, but unfortunately, therapy cannot be shortened within this population." The next step would be to investigate which patients would benefit from a shortened therapy duration. Cranendonk suggests this may be the case for elderly outpatients with comorbidity who are not severely ill.

The researchers enrolled 151 adult patients in 11 Dutch hospitals in the randomised, placebo-controlled, double-blind trial between 26 August 2014 and 29 June 2017. In double-blind trials, neither the investigators nor the patients know which patients receive the active medication or the placebo. Patients who had been treated successfully for six days and who had no fever and a lower cellulitis severity score were enrolled in the study.

The patients were randomised by diabetes status and location. Seventy-seven patients were allocated to receive another six days of intravenous flucloxacillin, while the remaining 74 patients received the placebo. The average age of the patients in this study was 63 and two-thirds were men. A quarter of the participants were diabetic, a population that is at a higher risk for cellulitis of the foot.

The trial was stopped early because of slow recruitment. Cranendonk warns that the results should be interpreted with caution because the researchers didn't reach their intended sample size.

"While the point estimate of the absolute risk reduction may be an indication of things to expect if our trial had reached its target, we cannot be certain there is no clinically significant difference between the two," he said. "As for the relapse rate at 90 days, the fact that the observed difference, even within this relatively small sample size, is statistically significant suggests there likely is an actual difference."
Abstract no: O1122, Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomised, double-blind, placebo-controlled, non-inferiority trial; Late breaker: Clinical trials, 16:00 - 18:00, Sunday, 22 April 2018, Hall Q

[1] The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). This year it will take place from 21 - 24 April 2018 in Madrid, Spain. At the world's largest congress combining the fields of infectious diseases and clinical microbiology, researchers will present more than 3,000 regular and late-breaking abstracts with the latest findings and recommendations, which are set to help improve diagnosis, prevention and treatment of infection-related diseases. The congress offers almost 200 sessions, including keynote lectures, symposia, oral sessions, educational workshops and meet-the-expert session. ECCMID expects approximately 13,000 participants from more than 100 countries.


The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is a non-profit organization dedicated to improving the diagnosis, treatment and prevention of infectious diseases in Europe and beyond. The society promotes and supports research, education, training and good medical practice in infection-related disciplines with a special focus on antimicrobial resistance to build capacity throughout the world. http://www.escmid.org


Chantal Britt
ESCMID Communications Manager
ESCMID Executive Office
P.O. Box 214, CH-4010 Basel
Phone +41-61-508-01-57
Mobile +41-76-588-08-24
Email chantal.britt@escmid.org

Tara Giroud
ECCMID Communications Assistant
Mobile +41-78-705-79-85
Email taragiroud@gmail.com

European Society of Clinical Microbiology and Infectious Diseases

Related Infectious Diseases Articles from Brightsurf:

Understanding the spread of infectious diseases
Physicists at M√ľnster University (Germany) have shown in model simulations that the COVID-19 infection rates decrease significantly through social distancing.

Forecasting elections with a model of infectious diseases
Election forecasting is an innately challenging endeavor, with results that can be difficult to interpret and may leave many questions unanswered after close races unfold.

COVID-19 a reminder of the challenge of emerging infectious diseases
The emergence and rapid increase in cases of coronavirus disease 2019 (COVID-19), a respiratory illness caused by a novel coronavirus, pose complex challenges to the global public health, research and medical communities, write federal scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) and from the Centers for Disease Control and Prevention (CDC).

Certain antidepressants could provide treatment for multiple infectious diseases
Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.

Opioid epidemic is increasing rates of some infectious diseases
The US faces a public health crisis as the opioid epidemic fuels growing rates of certain infectious diseases, including HIV/AIDS, hepatitis, heart infections, and skin and soft tissue infections.

Infectious diseases could be diagnosed with smartphones in sub-Saharan Africa
A new Imperial-led review has outlined how health workers could use existing phones to predict and curb the spread of infectious diseases.

The Lancet Infectious Diseases: Experts warn of a surge in vector-borne diseases as humanitarian crisis in Venezuela worsens
The ongoing humanitarian crisis in Venezuela is accelerating the re-emergence of vector-borne diseases such as malaria, Chagas disease, dengue, and Zika virus, and threatens to jeopardize public health gains in the country over the past two decades, warn leading public health experts.

Glow-in-the-dark paper as a rapid test for infectious diseases
Researchers from Eindhoven University of Technology (The Netherlands) and Keio University (Japan) present a practicable and reliable way to test for infectious diseases.

Math shows how human behavior spreads infectious diseases
Mathematics can help public health workers better understand and influence human behaviors that lead to the spread of infectious disease, according to a study from the University of Waterloo.

Many Americans say infectious and emerging diseases in other countries will threaten the US
An overwhelming majority of Americans (95%) think infectious and emerging diseases facing other countries will pose a 'major' or 'minor' threat to the U.S. in the next few years, but more than half (61%) say they are confident the federal government can prevent a major infectious disease outbreak in the US, according to a new national public opinion survey commissioned by Research!America and the American Society for Microbiology.

Read More: Infectious Diseases News and Infectious Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.